Government-funded study finds death risk in PPI-Plavix combo

03/3/2009 | Bloomberg

A study funded by the U.S. Department of Veterans Affairs showed that the combination of anti-clotting drug Plavix and stomach drugs known as proton pump inhibitors increased the risk of death or hospital readmission by 25%. A spokeswoman for Plavix maker Bristol-Myers Squibb said the company is working with the FDA to address the issue. She advised health care professionals to "re-evaluate the need for starting or continuing treatment" with the stomach medicines.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC